Get the Stockscreener App
8.6156
4.57%
0.3756
Foghorn Therapeutics Inc stock is traded at $8.6156, with a volume of 61,033.
It is up +4.57% in the last 24 hours and up +10.05% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$8.24
Open:
$8.02
24h Volume:
61,033
Relative Volume:
0.40
Market Cap:
$478.58M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-3.1444
EPS:
-2.74
Net Cash Flow:
$-119.33M
1W Performance:
+5.47%
1M Performance:
+10.05%
6M Performance:
+43.85%
1Y Performance:
+124.98%
1-Day Range:
$7.945
$8.73
1-Week Range:
$7.575
$8.76
52-Week Range:
$2.70
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Foghorn Therapeutics Reports Third Quarter Highlights - TipRanks
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update - GlobeNewswire
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Raymond James & Associates - Defense World
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk - Simply Wall St
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Increases By 9.1% - MarketBeat
Long Term Trading Analysis for (FHTX) - Stock Traders Daily
Foghorn Therapeutics Unveils Clinical Pipeline Progress - Yahoo Finance
Foghorn Therapeutics Announces First Patient Dosed with - GlobeNewswire
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors - The Manila Times
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective - The Bakersfield Californian
FHTXFoghorn Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
(FHTX) Investment Report - Stock Traders Daily
Foghorn Therapeutics to Participate in the BMO Oncology Summit - GlobeNewswire
Perceptive Advisors LLC Purchases Shares of 544,000 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Perceptive Advisors LLC Buys New Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - MarketBeat
Foghorn Therapeutics' SWOT analysis: chromatin biology pioneer's stock outlook - Investing.com
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Holdings Increased by Rhumbline Advisers - Defense World
Deerfield Management Company L.P. Series C Takes Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - MarketBeat
Deerfield Management Company L.P. Series C Purchases Shares of 2,518,500 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics exec sells over $360k in company stock By Investing.com - Investing.com South Africa
Bank of New York Mellon Corp Buys 18,664 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics exec sells over $360k in company stock - Investing.com India
(FHTX) Long Term Investment Analysis - Stock Traders Daily
Foghorn Therapeutics (FHTX) Stock Forecast and Price Target 2024 - MarketBeat
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase - Benzinga
Foghorn Therapeutics (NASDAQ:FHTX) Price Target Raised to $9.00 - MarketBeat
Market Insight: Foghorn Therapeutics Inc (FHTX)’s Notable Gain, Closing at 9.99 - The Dwinnex
Foghorn Therapeutics exec sells over $116k in company stock By Investing.com - Investing.com Australia
Foghorn Therapeutics exec sells over $116k in company stock - Investing.com India
Foghorn Therapeutics executive sells over $107k in company stock By Investing.com - Investing.com Australia
Foghorn Therapeutics executive sells over $107k in company stock - Investing.com India
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? - MSN
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Sees Large Increase in Short Interest - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Sees Large Volume Increase - MarketBeat
Insider Sale: Chief Scientific Officer Steven Bellon Sells 20,000 Shares of Foghorn ... - Yahoo Finance
Insider Sale: Chief Scientific Officer Steven Bellon Sells 20,000 Shares of Foghorn ... By GuruFocus - Investing.com Canada
Insider Sale: Chief Scientific Officer Steven Bellon Sells 20,00 - GuruFocus.com
Foghorn Soars To New High Ahead Of Key Clinical Trial Event - RTTNews
Foghorn Therapeutics (NASDAQ:FHTX) Reaches New 1-Year High at $9.22 - MarketBeat
Petri Dish: Dyne’s Duchenne data; Foghorn hires BMS leader - The Business Journals
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Panagora Asset Management Inc. - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Receives New Coverage from Analysts at Jefferies Financial Group - Defense World
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet - MSN
Foghorn Therapeutics appoints new Chief Business Officer - Investing.com
Foghorn Therapeutics Appoints Anna Rivkin, Ph.D. as Chief Business Officer - citybiz
Foghorn Therapeutics appoints Anna Rivkin as CBO - TipRanks
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):